home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2877.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
51 lines
Document 2877
DOCN M94A2877
TI Treatment of HIV-infected patients with advanced symptomatic disease
with WF10 solution (TCDO).
DT 9412
AU Busch HW; Christensen S; Reichelt D; Jahn S; Zidek W; Medizinische
Poliklinik, WWU Munster, Germany.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):204 (abstract no. PB0245). Unique
Identifier : AIDSLINE ICA10/94369698
AB OBJECTIVE: Since the chlorite-oxygen reaction product (TCDO) activates
cellular phagocytosis and killer systems such as monocytes-macrophages,
NK-cells and cytotoxic T-lymphocytes and has also been shown to exhibit
significant virucidal activity against HIV-particles, our aim was to
determine the clinical effect of WF10 solution (intravenous application
form of TCDO) in HIV-infected patients who are intolerant to
antiretroviral therapy. METHODS: 20 patients with advanced symptomatic
HIV-infection, CD4 cell counts < 200/microliters, who were intolerant to
AZT, ddC and ddI were included in a controlled study. All patients had
two or more of the following symptoms: body temperature > 38 degrees C,
night sweat and chills, > 10% weight loss, diarrhea, fatigue, PGL,
Kaposi's sarcoma, history of candidiasis or herpes zoster. 5 of 10
patients, whose data are presented in this abstract were p24 antigen
positive. WF10 solution was administered by i.v. infusion at a dosage of
0.5 ml/kg b.w. per day for 2 consecutive days and twice a day 0.25 ml/kg
b.w. for 3 consecutive days (= one treatment cycle) every 3 weeks for up
to 3 months (4 treatment cycles). RESULTS: First, during 13 weeks of
follow up no severe adverse reactions were seen. Second, one p24 antigen
(Ag) positive patient became negative, the average value of the p24 Ag
positive patients decreased by 25% under baseline value (b.v.). In one
case a p24 Ag negative patient became p24 positive, but was again
negative at the end of the study. Third, while the average of CD4 cell
count declined from 36 to 24/microliters, the average values of
lymphocytes increased from 658 to 721/microliters and of T-cells from
429 to 502/microliters. Furthermore, an increase of white blood cells
from 2656 to 3353/microliters, of granulocytes from 1467 to
2301/microliters and of thrombocytes from 170 to 201 x 103/microliters
was observed. Fourth, due to a remarkable effect on clinical symptoms,
the average of quality of life-index increased by 10% over b.v.
CONCLUSIONS: The initiation of WF10-therapy in symptomatic HIV-infected
patients with impaired immunity who are intolerant to AZT, ddC and ddI
appears to be of benefit.
DE Acquired Immunodeficiency Syndrome/DRUG THERAPY Adjuvants,
Immunologic/*THERAPEUTIC USE Antiviral Agents/*THERAPEUTIC USE
Chlorine/*THERAPEUTIC USE Human HIV Infections/*DRUG THERAPY
Immunity, Cellular/DRUG EFFECTS Leukocyte Count Oxides/*THERAPEUTIC
USE Treatment Outcome T4 Lymphocytes CLINICAL TRIAL MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).